Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 4/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | EGFR | P00533 | 1/20 | 0.34 |
| ▸ | MET | P08581 | 1/20 | 0.34 |
| ▸ | CDK4 | P11802 | 1/20 | 0.34 |
| ▸ | BRAF | P15056 | 1/20 | 0.34 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.34 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.34 |
| ▸ | CNR1 | P21554 | 6/20 | 0.34 |
| ▸ | CNR2 | P34972 | 5/20 | 0.34 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
| ▸ | DPP4 | P27487 | 1/20 | 0.32 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.32 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3578783 | 0.80 | HSP90AB1 (0.51) | — | |
| SCHEMBL16186389 | 0.80 | LRRK2 (0.46) | LRRK2DYRK1A | |
| SCHEMBL13543862 | 0.72 | LRRK2 (0.58) | LRRK2BRAF | |
| SCHEMBL3565489 | 0.72 | LRRK2 (0.72) | LRRK2KDM4E | |
| Methane SCHEMBL3579468 | 0.72 | LRRK2 (0.57) | LRRK2BRAF | |
| SCHEMBL16177865 | 0.71 | LRRK2 (0.42) | LRRK2DYRK1A | |
| SCHEMBL10852761 | 0.70 | KDM4E (0.46) | KDM4EMAPTTDP1EGFRMET | |
| SCHEMBL3572423 | 0.69 | LRRK2 (0.49) | LRRK2KDM4EMAPTTDP1CNR1 | |
| SCHEMBL3581459 | 0.65 | LRRK2 (0.61) | LRRK2 | |
| SCHEMBL1133474 | 0.65 | KDM4E (0.43) | KDM4EMAPTTDP1DYRK1ACNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100010037-A1 | 1H-PYRROLO[2,3-B]PYRIDINE DERIVATIVES USEFUL AS HSP90 INHIBITORS | VERNALIS (R&D) LTD. (GB) | 2010-01-14 | — | — | US | disclosed |
| US-20100010037-A1 | 1H-PYRROLO[2,3-B]PYRIDINE DERIVATIVES USEFUL AS HSP90 INHIBITORS | VERNALIS (R&D) LTD. (GB) | 2010-01-14 | — | — | US | disclosed |
| EP-2057155-A1 | 1H-PYRROLO[2,3-B]PYRIDINE DERIVATIVES USEFUL AS HSP90 INHIBITORS | Vernalis (R&D) Limited (GB) | 2009-05-13 | — | — | EP | disclosed |
| WO-2008025947-A1 | 1H-PYRROLO[2,3-B]PYRIDINE DERIVATIVES USEFUL AS HSP90 INHIBITORS | VERNALIS (R & D) LTD. (GB) | 2008-03-06 | — | — | WO | disclosed |
| WO-2008025947-A1 | 1H-PYRROLO[2,3-B]PYRIDINE DERIVATIVES USEFUL AS HSP90 INHIBITORS | VERNALIS (R & D) LTD. (GB) | 2008-03-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100010037-A1 | 1H-PYRROLO[2,3-B]PYRIDINE DERIVATIVES USEFUL AS HSP90 INHIBITORS | HSP90AB1, HSP90AA1, HSP90AB2P | LRRK2 2502/4885KDM4E 3920/4885MAPT 3387/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.